| Factor Information | |
|---|---|
| Data ID | 4125 |
| Factor | Prescriptions in the first three months of pregnancy of the anti-clotting medication aspirin |
| Description | Prescriptions in the first three months of pregnancy of the anti-clotting medication enoxaparin was associated with CHD and to a lesser extent aspirin (OR 2.07, 95%CI 1.11–3.85, adjOR 1.73, 95%CI 0.86–3.47. |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | risk assessment |
| Objective | To investigate the role of maternal environmental factors in the aetiology of CHD. |
| OR | 1.73 |
| Conclusion | Prescriptions in the first three months of pregnancy of the anti-clotting medication enoxaparin was associated with CHD and to a lesser extent aspirin. |
| Risk Factor | risk factor |
| CHD Type | |
|---|---|
| ID | 749 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | anomalies of the venous return/ASD/AVSD, OPD/AVC/HLHS/VSD/TOF, TGA/CoA/CACA |
| Reference | |
|---|---|
| PMID | 32092068 |
| Year | 2020 |
| Title | Risk factors for congenital heart disease: The Baby Hearts Study, a population-based case-control study |
| Sample | ||
|---|---|---|
| Population | adults(mother of CHD offspring) | |
| Source | mother of CHD offspring | |
| Region | Belfast,Northern Ireland, United Kingdom | |
| Method | univariable analysis; multivariate analysis | |
| Race | Eupopean | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | CHD cases(Treatment) | controls(Control) |
| Number | 16 | 33 |
| Age | N/A | N/A |
| Gender (Male: Female) | female | female |
| Marker Level | 16(6.61%) | 32(3.31%) |
